200 related articles for article (PubMed ID: 30097905)
21. Augmentation of response to chemotherapy by microRNA-506 through regulation of RAD51 in serous ovarian cancers.
Liu G; Yang D; Rupaimoole R; Pecot CV; Sun Y; Mangala LS; Li X; Ji P; Cogdell D; Hu L; Wang Y; Rodriguez-Aguayo C; Lopez-Berestein G; Shmulevich I; De Cecco L; Chen K; Mezzanzanica D; Xue F; Sood AK; Zhang W
J Natl Cancer Inst; 2015 Jul; 107(7):. PubMed ID: 25995442
[TBL] [Abstract][Full Text] [Related]
22. Identifying genes as potential prognostic indicators in patients with serous ovarian cancer resistant to carboplatin using integrated bioinformatics analysis.
Zhan SJ; Liu B; Linghu H
Oncol Rep; 2018 Jun; 39(6):2653-2663. PubMed ID: 29693178
[TBL] [Abstract][Full Text] [Related]
23. Exploring the Clinical Impact of Predictive Biomarkers in Serous Ovarian Carcinomas.
Le Page C; Chung J; Rahimi K; Köbel M; Provencher D; Mes-Masson AM
Curr Drug Targets; 2020; 21(10):974-995. PubMed ID: 31622218
[TBL] [Abstract][Full Text] [Related]
24. Diffuse mesothelin expression correlates with prolonged patient survival in ovarian serous carcinoma.
Yen MJ; Hsu CY; Mao TL; Wu TC; Roden R; Wang TL; Shih IeM
Clin Cancer Res; 2006 Feb; 12(3 Pt 1):827-31. PubMed ID: 16467095
[TBL] [Abstract][Full Text] [Related]
25. Identification of high-grade serous ovarian cancer miRNA species associated with survival and drug response in patients receiving neoadjuvant chemotherapy: a retrospective longitudinal analysis using matched tumor biopsies.
Petrillo M; Zannoni GF; Beltrame L; Martinelli E; DiFeo A; Paracchini L; Craparotta I; Mannarino L; Vizzielli G; Scambia G; D'Incalci M; Romualdi C; Marchini S
Ann Oncol; 2016 Apr; 27(4):625-34. PubMed ID: 26782955
[TBL] [Abstract][Full Text] [Related]
26. Network-Based Integration of GWAS and Gene Expression Identifies a HOX-Centric Network Associated with Serous Ovarian Cancer Risk.
Kar SP; Tyrer JP; Li Q; Lawrenson K; Aben KK; Anton-Culver H; Antonenkova N; Chenevix-Trench G; ; ; Baker H; Bandera EV; Bean YT; Beckmann MW; Berchuck A; Bisogna M; Bjørge L; Bogdanova N; Brinton L; Brooks-Wilson A; Butzow R; Campbell I; Carty K; Chang-Claude J; Chen YA; Chen Z; Cook LS; Cramer D; Cunningham JM; Cybulski C; Dansonka-Mieszkowska A; Dennis J; Dicks E; Doherty JA; Dörk T; du Bois A; Dürst M; Eccles D; Easton DF; Edwards RP; Ekici AB; Fasching PA; Fridley BL; Gao YT; Gentry-Maharaj A; Giles GG; Glasspool R; Goode EL; Goodman MT; Grownwald J; Harrington P; Harter P; Hein A; Heitz F; Hildebrandt MA; Hillemanns P; Hogdall E; Hogdall CK; Hosono S; Iversen ES; Jakubowska A; Paul J; Jensen A; Ji BT; Karlan BY; Kjaer SK; Kelemen LE; Kellar M; Kelley J; Kiemeney LA; Krakstad C; Kupryjanczyk J; Lambrechts D; Lambrechts S; Le ND; Lee AW; Lele S; Leminen A; Lester J; Levine DA; Liang D; Lissowska J; Lu K; Lubinski J; Lundvall L; Massuger L; Matsuo K; McGuire V; McLaughlin JR; McNeish IA; Menon U; Modugno F; Moysich KB; Narod SA; Nedergaard L; Ness RB; Nevanlinna H; Odunsi K; Olson SH; Orlow I; Orsulic S; Weber RP; Pearce CL; Pejovic T; Pelttari LM; Permuth-Wey J; Phelan CM; Pike MC; Poole EM; Ramus SJ; Risch HA; Rosen B; Rossing MA; Rothstein JH; Rudolph A; Runnebaum IB; Rzepecka IK; Salvesen HB; Schildkraut JM; Schwaab I; Shu XO; Shvetsov YB; Siddiqui N; Sieh W; Song H; Southey MC; Sucheston-Campbell LE; Tangen IL; Teo SH; Terry KL; Thompson PJ; Timorek A; Tsai YY; Tworoger SS; van Altena AM; Van Nieuwenhuysen E; Vergote I; Vierkant RA; Wang-Gohrke S; Walsh C; Wentzensen N; Whittemore AS; Wicklund KG; Wilkens LR; Woo YL; Wu X; Wu A; Yang H; Zheng W; Ziogas A; Sellers TA; Monteiro AN; Freedman ML; Gayther SA; Pharoah PD
Cancer Epidemiol Biomarkers Prev; 2015 Oct; 24(10):1574-84. PubMed ID: 26209509
[TBL] [Abstract][Full Text] [Related]
27. Ubiquitin-Proteasome Axis, Especially Ubiquitin-Specific Protease-17 (
Yildirim N; Kocal GC; Isik Z; Saatli B; Saygili U; Uysal T; Ulukus C; Koyuncuoglu M; Ellidokuz H; Basbinar Y
Reprod Sci; 2019 Jun; 26(6):794-805. PubMed ID: 30198418
[TBL] [Abstract][Full Text] [Related]
28. Genomic profiling of the residual disease of advanced high-grade serous ovarian cancer after neoadjuvant chemotherapy.
Lee YJ; Kim D; Shim JE; Bae SJ; Jung YJ; Kim S; Lee H; Kim SH; Jo SB; Lee JY; Kim HS; Paik S
Int J Cancer; 2020 Apr; 146(7):1851-1861. PubMed ID: 31603993
[TBL] [Abstract][Full Text] [Related]
29. Mechanisms of Drug Resistance in High-Grade Serous Ovarian Cancer.
Freimund AE; Beach JA; Christie EL; Bowtell DDL
Hematol Oncol Clin North Am; 2018 Dec; 32(6):983-996. PubMed ID: 30390769
[TBL] [Abstract][Full Text] [Related]
30. High expression of RIPK2 is associated with Taxol resistance in serous ovarian cancer.
Shen Y; Lin H; Chen K; Ge W; Xia D; Wu Y; Lu W
J Ovarian Res; 2022 Apr; 15(1):48. PubMed ID: 35477477
[TBL] [Abstract][Full Text] [Related]
31. Research on the Potential Mechanism of Gypenosides on Treating Thyroid-Associated Ophthalmopathy Based on Network Pharmacology.
Li K; Li H; Xu W; Liu W; Du Y; He JF; Ma C
Med Sci Monit; 2019 Jul; 25():4923-4932. PubMed ID: 31268042
[TBL] [Abstract][Full Text] [Related]
32. A Five-Gene Expression Signature Predicts Clinical Outcome of Ovarian Serous Cystadenocarcinoma.
Liu LW; Zhang Q; Guo W; Qian K; Wang Q
Biomed Res Int; 2016; 2016():6945304. PubMed ID: 27478834
[TBL] [Abstract][Full Text] [Related]
33. Comparison of tumor related signaling pathways with known compounds to determine potential agents for lung adenocarcinoma.
Xu S; Liu R; Da Y
Thorac Cancer; 2018 Aug; 9(8):974-988. PubMed ID: 29870138
[TBL] [Abstract][Full Text] [Related]
34. Low Grade Serous Ovarian Carcinoma: from the molecular characterization to the best therapeutic strategy.
Della Pepa C; Tonini G; Santini D; Losito S; Pisano C; Di Napoli M; Cecere SC; Gargiulo P; Pignata S
Cancer Treat Rev; 2015 Feb; 41(2):136-43. PubMed ID: 25573350
[TBL] [Abstract][Full Text] [Related]
35. Glucocorticoid receptor activation inhibits chemotherapy-induced cell death in high-grade serous ovarian carcinoma.
Stringer-Reasor EM; Baker GM; Skor MN; Kocherginsky M; Lengyel E; Fleming GF; Conzen SD
Gynecol Oncol; 2015 Sep; 138(3):656-62. PubMed ID: 26115975
[TBL] [Abstract][Full Text] [Related]
36. Prognostic Role of Zinc Finger Homeobox 4 in Ovarian Serous Cystadenocarcinoma.
Ha M; Kim J; Park SM; Hong CM; Han ME; Song P; Kang CD; Lee D; Kim YH; Hur J; Oh SO
Genet Test Mol Biomarkers; 2020 Mar; 24(3):145-149. PubMed ID: 32105524
[No Abstract] [Full Text] [Related]
37. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs.
Chen S; Jiao JW; Sun KX; Zong ZH; Zhao Y
Drug Des Devel Ther; 2015; 9():5225-35. PubMed ID: 26396496
[TBL] [Abstract][Full Text] [Related]
38. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
[No Abstract] [Full Text] [Related]
39. Revealing active ingredients, potential targets, and action mechanism of Ermiao fang for treating endometritis based on network pharmacology strategy.
Zhang C; Su T; Yu D; Wang F; Yue C; Wang HQ
J Ethnopharmacol; 2020 Oct; 260():113051. PubMed ID: 32505843
[TBL] [Abstract][Full Text] [Related]
40. Network Pharmacology-Based Study on the Molecular Biological Mechanism of Action for Compound Kushen Injection in Anti-Cancer Effect.
He R; Ou S; Chen S; Ding S
Med Sci Monit; 2020 Jan; 26():e918520. PubMed ID: 31892693
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
